Join
Live feed
·
PRReleasevia Quantisnow
Angion Biomedica Corp. logo

Angion and Vifor Pharma Report Topline Results from Phase 3 Trial of ANG-3777 in Kidney Transplant Patients at Risk for Delayed Graft Function

ByQuantisnow·Wall Street's wire, on your screen.
ANGN· Angion Biomedica Corp.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ANGN (Angion Biomedica Corp.) and more on Quantisnow.